Quantum Biopharma Class B Subordinate Voting Shares
QNTM
25 hedge funds and large institutions have $1.23M invested in Quantum Biopharma Class B Subordinate Voting Shares in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 5 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
31% more capital invested
Capital invested by funds: $937K → $1.23M (+$290K)
4% more funds holding
Funds holding: 24 → 25 (+1)
3.3% more ownership
Funds ownership: 3.36% → 6.66% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$266K |
| 2 |
PTP
Platform Technology Partners
New York
|
+$185K |
| 3 |
Jane Street
New York
|
+$92.9K |
| 4 |
Mariner
Overland Park,
Kansas
|
+$45.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$24.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
-$89.8K |
| 2 |
JP Morgan Chase
New York
|
-$4.21K |
| 3 |
Morgan Stanley
New York
|
-$1.77K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$162 |
| 5 |
SEP
Signature Equity Partners
Columbus,
Ohio
|
-$146 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
JP Morgan Chase
New York
| – | -$4.21K | -577 | Closed |
|
|
27
Morgan Stanley
New York
| – | -$1.77K | -243 | Closed |
|
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$162 | -36 | -65% |
|
|
SEP
29
Signature Equity Partners
Columbus,
Ohio
| – | -$146 | -20 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$29 | -4 | Closed |
|
QNTM Hedge Fund Activity: Q1 2026 in Review
25 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q1 2026, worth a combined $1.23M — up 31% from $937K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new QNTM positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $266K. The largest seller was GTS Securities, exiting entirely with an estimated $89.8K sold.
- 25 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q1 2026, up from 24 in Q4 2025.
- Funds reported $1.23M of Quantum Biopharma Class B Subordinate Voting Shares stock for Q1 2026, up 31% quarter-over-quarter.
- 7 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q1 2026 and 5 closed out, a net change of +2 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q1 2026 was AdvisorShares Investments, an estimated $266K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q1 2026 was GTS Securities, an estimated $89.8K sold.
Based on aggregated 13F filings for Q1 2026.